Parkside Financial Bank & Trust lowered its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 24.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 295 shares of the medical research company's stock after selling 93 shares during the period. Parkside Financial Bank & Trust's holdings in IQVIA were worth $64,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in IQV. Regatta Capital Group LLC boosted its stake in shares of IQVIA by 2.5% in the 1st quarter. Regatta Capital Group LLC now owns 2,024 shares of the medical research company's stock worth $468,000 after buying an additional 50 shares during the last quarter. Private Capital Group LLC raised its holdings in IQVIA by 8.9% during the first quarter. Private Capital Group LLC now owns 659 shares of the medical research company's stock valued at $152,000 after acquiring an additional 54 shares during the period. Waldron Private Wealth LLC raised its holdings in IQVIA by 4.4% during the first quarter. Waldron Private Wealth LLC now owns 1,389 shares of the medical research company's stock valued at $321,000 after acquiring an additional 59 shares during the period. Vestmark Advisory Solutions Inc. raised its holdings in IQVIA by 6.7% during the first quarter. Vestmark Advisory Solutions Inc. now owns 952 shares of the medical research company's stock valued at $220,000 after acquiring an additional 60 shares during the period. Finally, Peterson Wealth Services grew its position in shares of IQVIA by 5.7% during the second quarter. Peterson Wealth Services now owns 1,105 shares of the medical research company's stock valued at $240,000 after purchasing an additional 60 shares in the last quarter. 86.77% of the stock is currently owned by hedge funds and other institutional investors.
Get IQVIA alerts:Wall Street Analysts Forecast Growth
Several research analysts recently commented on the company. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday. SVB Leerink started coverage on shares of IQVIA in a research note on Friday, July 15th. They issued an "outperform" rating and a $256.00 price objective for the company. Robert W. Baird boosted their price objective on shares of IQVIA from $260.00 to $265.00 in a research note on Friday, July 22nd. Evercore ISI upped their price target on IQVIA from $265.00 to $275.00 in a research report on Friday, July 22nd. Finally, Morgan Stanley upped their price target on IQVIA from $255.00 to $260.00 and gave the stock an "overweight" rating in a research report on Friday, July 22nd. Two investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $275.00.
IQVIA Stock Down 0.6 %
IQV opened at $189.43 on Friday. The company has a market cap of $35.33 billion, a PE ratio of 31.62, a price-to-earnings-growth ratio of 1.74 and a beta of 1.34. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 2.36. IQVIA Holdings Inc. has a twelve month low of $186.24 and a twelve month high of $285.61. The company has a 50-day moving average price of $223.04 and a 200 day moving average price of $219.92.IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 EPS for the quarter, beating analysts' consensus estimates of $2.22 by $0.22. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.49 billion. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. IQVIA's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.94 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 9.4 earnings per share for the current fiscal year.
About IQVIA
(Get Rating)
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.